Results of definitive combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine administration;Ergebnisse der primaren kombinierten radiochemotherapie von kopf-hals- tumoren mit simultaner speicheldrusenprotektion durch amifostin

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL.4, 1999, Pages 13-17

  Schultze, Jürgen ^a   Kimmig, Bernhard ^a  

^a NONE

Author keywords

Amifostine; Cytoprotection; Head and neck tumor; Radiation therapy

Indexed keywords

AMIFOSTINE; CARBOPLATIN; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT;

ARTICLE; CLINICAL ARTICLE; DERMATITIS; HEAD TUMOR; HUMAN; HYPOTENSION; NAUSEA; NECK TUMOR; RADIATION PROTECTION; SALIVARY GLAND FUNCTION; SKIN PIGMENTATION; XEROSTOMIA; COMPARATIVE STUDY; DRUG EFFECT; HEAD AND NECK TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION EXPOSURE; SALIVARY GLAND; SCINTISCANNING; TIME; TREATMENT OUTCOME;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE; SALIVARY GLANDS; TIME FACTORS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0032726592     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bohuslavizki KH, Brenner W, Lassmann S. et al. Die quantitative Sialoszintigraphie - eine sinnvolle Untersuchung im Vorfeld und in der Nachsorge der Radiojodthcrapie. Nuklearmedizin 1997;36:103-9.
2. Bünlzel J. Glatzel M, Schuth J. et al. Einsatz von Amifostin hei simultaner Radiochcmotherapie von HNO-Tumoren - eine Phase I/II-Studie. Z Onkol 1996;28:42-9.
3. Büntzel J. Küttner K. Russell L, et al. Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proc ASCO 1997;16:1400.
4. Busch M. Schymura B. Dühmke E. Cytoprotection with amifostine in recurrent head and neck cancer. Proc ASCO 1997;16:1418.
5. Ewald H, Feulner Q. Mucositisprotektion durch GCSF bei Radio-/Chemotherapie von Patienten mit fortgeschrittenen Tumoren im Kopf-/Hals-bereich? Eine Pilotstudic. Radiologe 1998:38:155.
6. McDonald S, Meyetowitz C, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29: 747-54.
7. Planting AST. Vermerken JB. Catimet G. et al. Randomized phase II study of weekly cisplatin with or without amifostinc in patients with advanced head and neck cancer. Proc ASCO 1996:15:887.
8. Schultze J, Bohuslavizki KH, Kimmig B. Speicheldrüsenprotektion mit Amifoslin bei der Strahlentherapie von Kopl/Halstumoren - Erste klinische und szintigraphische Ergebnisse. Radiologe 1997;37:118.
9. Tannehill SP, Mehta MP. Amifostine and radiation therapy: past, present, and future. Semin Oncol 1996;23.4:Suppl 8:69-77.
10. Wasserman TH. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol 1994;21.5:Suppl 2:21-5.
11. Wasserman TH, Chapman JD, Colenian CN, et al. Chemical modifiers of radiation. In: Perez CA, Brady LW, eds. Principles and practice of radiation oncology. Philadelphia: Lippincott-Raven, 1997:685-704.